| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.076 | 0.1 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.1 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.047 | 0.1 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.073 | 0.1 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |